Project Grant R21AI200510
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $194,375 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded on May 4, 2026, with a completion date of April 30, 2028. This research initiative focuses on HIV latency reversal through targeted bromodomain-containing protein 4 (BRD4) recruitment, addressing a critical gap in HIV cure strategies. The...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $427,625 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on continued human immunodeficiency virus (HIV) production from infected macrophages in people on antiretroviral therapy (ART). The award, initiated on June 10, 2026, with a completion date of May 31, 2028, will fund...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of North Carolina at Chapel Hill $1,414,502 on August 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to assess antiretroviral (ARV) tissue penetration variability using multimodal imaging techniques. This five-year project (concluding July 31, 2030) investigates how HIV persists in tissue viral reservoirs during antiretroviral treatment and how...
- Federal Grant Award Summary East Carolina University received a $536,695 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective May 1, 2026, through April 30, 2027. The award supports investigator-initiated biomedical research focused on elucidating the roles of fibroblastic reticular cells (FRCs), a type of secondary lymphoid organ stromal cell, in the establishment and...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $2.94 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 18, 2025, with a completion date of July 31, 2029. This award supports the development and clinical advancement of ACE2 immunodecoys as long-lasting immunoprophylaxis against sarbecoviruses and merbecoviruses that target...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $1,171,275 Project Grant awarded May 8, 2026, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research deliverables focus on developing and evaluating a combined therapeutic countermeasure to achieve functional cure of HIV-1 infection through integration of two immunological approaches: a CD8 T cell...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $806,623 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 29, 2026, with completion targeted for April 30, 2027. The research deliverables focus on elucidating the structural and kinetic mechanisms of HIV-1 broadly neutralizing antibody (bNAb) interactions, specifically...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of North Carolina at Chapel Hill a Project Grant of $115,123.00 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 20, 2025, with a completion date of July 31, 2027. This research project, titled "Inside Out: Revealing Strategies for Intracellular S. Aureus Persister Eradication," addresses the critical challenge of antibiotic-tolerant...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $421,067 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 8, 2025, with a completion date of July 31, 2027. This research initiative delivers scientific investigation and experimental research services focused on understanding the mechanisms by which neutrophil extracellular traps...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of North Carolina at Chapel Hill $420,553 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel single-cell measurement technologies and conduct fundamental research on antibiotic tolerance in bacterial populations. The award, effective August 8, 2025 through July 31, 2027, funds the design and implementation of a single-cell technique capable...
The University of North Carolina at Chapel Hill received a $427,625 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 15, 2026, with completion anticipated by May 31, 2028. The award supports research aimed at identifying immune signatures associated with HIV reservoir characteristics and clonal expansion in people with HIV (PWH) on antiretroviral therapy (ART). The research will employ single-cell transcriptomic and proteomic analysis across a cohort of 125 ART-suppressed PWH with well-characterized HIV reservoirs to comprehensively define the relationship between immune system function and HIV reservoir persistence, while quantifying reservoir clonality and defining immune signatures associated with infected cell expansion. The deliverables from this research initiative include detailed correlational analyses linking transcriptomic and proteomic immune signatures with key HIV reservoir characteristics, including size, transcriptional activity, and clonal expansion patterns. These findings are intended to identify molecular pathways contributing to reservoir-immune system crosstalk that could potentially be targeted therapeutically to limit both HIV reservoir persistence and associated pathology in PWH on long-term ART. The research addresses a critical gap in understanding chronic immune dysfunction observed in virally suppressed individuals, despite effective antiretroviral treatment.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $427.6k | 6/16/26 |